Gene Therapy's Future Can Be NAV-igated Alone, REGENXBIO CEO Says
This article was originally published in Scrip
Executive Summary
Having netted $148m in its September initial public offering, REGENXBIO, Inc. is moving toward the clinic with its first two gene therapy candidates and believes it – and its licensees – are positioned to succeed in gene therapy where earlier attempts failed. Coming out of a "quiet period" after its IPO, which sold 7.2 million shares at $22 apiece, REGENXBIO CEO Kenneth Mills talked to Scrip's sister publication "The Pink Sheet" DAILY about his company's plans and strategies, as well as why its novel adeno-associated virus (NAV) vectors might be more viable than the first iteration of AAV-based therapies.
You may also be interested in...
Biogen Shores Up Gene Therapy Ambitions With New Deal
Biogen Inc. has furthered its gene therapy ambitions by entering into a broad alliance with the University of Pennsylvania that could see it paying out up to $2bn in research funding and other payments. Biogen has made a series of moves over the past couple of years to build up its gene therapy research.
Deal Watch: Six Small Biopharma Mergers Reflect Recent Trend
M&A edition: Mergers by Century/Clade, Eliem/Tenet, Kintara/TuHURA, Aditxt/Appili, Onconova/Traws and Apotex/Searchlight follow other companies joining forces in a tight cash environment.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.